Verzenios® ▼ (abemaciclib): ER-/PR+ Patienter i MONARCH-Studierna

Detailed Information

In the MONARCH-2 and MONARCH-3 clinical trials, patients were required to have HR+ disease to be included in the studies.^1,2

Patients in the MONARCH-2 and MONARCH-3 studies who were ER- and PR+ are presented in Table 1.

Table 1. ER-/PR+ Patients in the MONARCH-2 and MONARCH-3 Clinical Trials³

Abbreviations: ER- = estrogen receptor-negative; ITT = intent-to-treat; NSAI = nonsteroidal aromatase inhibitor; PR+ = progesterone receptor-positive.

Due to the small number of patients with ER-/PR+ disease, efficacy and safety analyses are not available for this subgroup.

References

1. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646. https://doi.org/10.1200/jco.2017.75.6155

2. Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. http://dx.doi.org/10.1200/JCO.2017.73.7585

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

ER- = estrogen receptor-negative

HR+ = hormone receptor-positive

PR+ = progesterone receptor-positive

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.